CIK 0001640266
- Accelerated filer
- Smaller reporting company
Voyager Therapeutics, Inc.
Sign in to watch- Ticker
- VYGR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 857-259-5340
- Business address
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-03-23 | Henderson Jane Sr. V.P. & CFO, Corp. Dev. | Sale | −11,200 | $20.52 | $230K | 0 |
| 2018-03-23 | Henderson Jane Sr. V.P. & CFO, Corp. Dev. | Exercise or conversion · Stock Option (Right to Buy) | −11,200 | 165,584 | ||
| 2018-03-22 | Henderson Jane Sr. V.P. & CFO, Corp. Dev. | Exercise or conversion | +19,900 | $11.97 | $238K | 19,900 |
| 2018-03-22 | Henderson Jane Sr. V.P. & CFO, Corp. Dev. | Sale | −19,900 | $21.07 | $419K | 0 |
| 2018-03-22 | Henderson Jane Sr. V.P. & CFO, Corp. Dev. | Exercise or conversion · Stock Option (Right to Buy) | −19,900 | 176,784 | ||
| 2018-03-19 | Henderson Jane CFO & SVP, Corp. Dev. | Exercise or conversion | +1,900 | $11.97 | $23K | 1,900 |
| 2018-03-19 | Henderson Jane CFO & SVP, Corp. Dev. | Sale | −1,900 | $21.76 | $41K | 0 |
| 2018-03-19 | Henderson Jane CFO & SVP, Corp. Dev. | Exercise or conversion · Stock Option (Right to Buy) | −1,900 | 196,684 | ||
| 2018-03-16 | Henderson Jane CFO & SVP, Corp. Dev. | Exercise or conversion | +15,416 | $11.97 | $185K | 15,416 |
| 2018-03-16 | Henderson Jane CFO & SVP, Corp. Dev. | Sale | −15,416 | $22.15 | $341K | 0 |
| 2018-03-16 | Henderson Jane CFO & SVP, Corp. Dev. | Exercise or conversion · Stock Option (Right to Buy) | −15,416 | 198,584 | ||
| 2018-03-12 | Ravina Bernard Chief Medical Officer | Sale | −2,451 | $25.16 | $62K | 2,451 |
| 2018-03-07 | PAUL STEVEN M Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2018-03-07 | Ottmer Matthew P. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2018-03-07 | Sah Dinah Ph.D. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2018-03-07 | Ravina Bernard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2018-03-07 | Henderson Jane Sr. V.P. & CFO | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2018-02-27 | Sah Dinah Ph.D. Chief Scientific Officer | Exercise or conversion | −2,184 | $7.27 | $16K | 140,872 |
| 2018-02-27 | Sah Dinah Ph.D. Chief Scientific Officer | Exercise or conversion | −4,376 | $8.33 | $36K | 145,248 |
| 2018-02-27 | Sah Dinah Ph.D. Chief Scientific Officer | Exercise or conversion | −5,000 | $11.09 | $55K | 150,248 |
Page 16 of 19 · 368 trades